Sino and AstraZeneca sign licence agreement for TQC3721

AstraZeneca and Sino Biopharmaceutical's subsidiary CTTQ have signed an exclusive licence agreement for TQC3721. Sino Biopharmaceutical will receive an upfront payment of $200m from AstraZeneca. The agreement covers certain future development programmes on an exclusive worldwide basis for AstraZeneca. Credit: Jose Eduardo Rubio / Shutterstock.com. AstraZeneca and Sino Biopharmaceutical’s subsidiary Chia Tai Tianqing Pharmaceutical Group (CTTQ) have signed an exclusive licence agreement for TQC3721. AstraZeneca will obtain a licence to develop, manufacture and commercialise the phosphodiesterase 3/4 (PDE3/4) inhibitor, TQC3721, outside China. NPVM: AstraZeneca Plc's AZD-8205 Reports NPVM: AstraZeneca Plc's AZD-9567 Go deeper with GlobalData The gold standard of business…

Source: Pharmaceutical Technology